Drug-Eluting Balloons: Coming of Age in the Periphery
The jury is still on the ultimate utility of stenting and atherectomy in the distal periphery; meanwhile, all eyes are now on an extremely promising new technology that could be a game-changer for this arena: drug-eluting balloons. DEBs are basically angioplasty balloons coated with an antirestenosis drug that is delivered directly to the vessel wall at the time of balloon inflation. They offer numerous advantages over drug-eluting stents in the superficial femoral artery and distal vessels since they leave no implant behind in the vessel that can fracture or cause hypersensitivity reactions and they eliminate the worries of in-stent restenosis and late-stent thrombosis.They may also provide more uniform distribution of the antiproliferative drug in the vessel wall than stents.
by Mary Thompson
The jury is still out with regards to the ultimate utility of stenting and atherectomy in the distal periphery (see "The Next Wave in Peripheral Vascular Interventions," this issue Also...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.